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ABSTRACT
Introduction: The aim of this study was to use
multiple data sources to update information on
gastrointestinal perforations (GIPs) during
tocilizumab (TCZ) treatment in patients with
rheumatoid arthritis (RA).
Methods: Reporting rates of GIP events were
estimated from three distinct patient data sets: a
TCZ-IV RA clinical trial all-exposure population,
a global TCZ postmarketing safety database
population, and a US healthcare claims
database population of patients with RA,
including patients who received TCZ,
anti-tumor necrosis factor (aTNF) agents, or
abatacept.
Results: The clinical trial, global
postmarketing, and healthcare claims
populations provided 17,906, 382,621, and
3268 patient-years (PYs) of TCZ exposure,
respectively. GIP incidence rates [95%
confidence interval (CI)] were 1.9 (1.3–2.7), 1.2
(1.1–1.3), and 1.8 (0.7–4.0; specific definition)
to 2.8 (1.3–5.2; sensitive definition) per 1000
PYs for the clinical trial, postmarketing, and
healthcare claims populations, respectively. The
GIP incidence rate (95% CI) for the comparator
aTNF healthcare claims population ranged from
0.6 (0.3–1.2) to 0.9 (0.5–1.5) per 1000 PYs, for
an absolute rate difference between TCZ and
aTNFs of 1.2 (-0.3 to 2.5) to 1.9 (0.0–3.7) per
1000 PYs, corresponding to a number needed to
harm between 533 and 828.
Conclusion: The TCZ GIP event rates from
multiple data sources were consistent with
previously reported rates, did not increase over
time, and were significantly associated with the
number of prior biologics. Comparison of GIP
incidence rates among patients with prior
biologic exposure suggests that, for every 1000
patients treated with TCZ per year, an
additional 1–2 GIP events might occur
compared with patients treated with aTNFs.
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antirheumatic drugs (csDMARDs) are the first
choice of treatment for patients with
rheumatoid arthritis (RA); however, for the
approximately 50–70% of patients with RA
who do not respond adequately to csDMARDs
alone, therapy with a biologic DMARD is
recommended [1–3]. Biologic DMARDs
currently indicated for RA include five
anti-tumor necrosis factor (aTNF) agents, the
anti-interleukin 6 receptor therapy tocilizumab
(TCZ), the B-cell-targeted therapy rituximab,
and the T-cell costimulatory modulator
abatacept. The 2013 update of the European
League Against Rheumatism (EULAR)
recommendations for the management of RA
state that in patients with an incomplete
response to methotrexate and/or other
csDMARDs, biologic DMARDs should be
started in combination with methotrexate [4].
The EULAR Task Force regards all currently
approved biologic DMARDs as being similarly
effective (with the exception of anakinra) and
generally safe for use as an initial biological
therapy after csDMARD failure. Similarly, no
specific biologic DMARD recommendation was
made if patients failed their first biologic
DMARD; patients should be treated with
another biologic DMARD with a similar or
different mechanism of action.
TCZ is a humanized monoclonal
anti-interleukin 6 receptor antibody; its safety
and efficacy have been demonstrated in[5000
patients with RA in randomized controlled trials
andtheir long-termextensions, asmonotherapyor
in combination with csDMARDs [5–13]. Based on
these clinical trials, TCZ was approved to treat RA
in the European Union in 2009 and in the United
States (US) in 2010. It is currently indicated to treat
adult RA [intravenously (IV) and subcutaneously
(SC)] and systemic- and polyarticular-course
juvenile idiopathic arthritis (IV).
A study by Curtis et al. [14] evaluated the
overall safety of TCZ in patients with RA using
TCZ data from a large postmarketing safety
database (cutoff date July 29, 2011) and clinical
trials (cutoff date April 1, 2011) and aTNF
comparator data from a US external healthcare
insurance claims database (January 1, 2010 to
June 30, 2014) and published literature. The
overall risk of serious adverse events (SAEs)
associated with TCZ treatment was not greater
than with aTNF agents.
It was also shown in the analyses by Curtis
et al. [14] that the rates of certain TCZ-related
safety events of special interest—including
serious hepatic events, serious gastrointestinal
(GI) events, serious myocardial infarctions,
serious strokes, and cardiac deaths—were
similar to corresponding rates from the aTNF
comparator population. Of particular interest,
GI perforation (GIP) is a rare but serious adverse
drug reaction that has been observed in relation
to medications for RA and is also listed under
the warnings and precautions of the TCZ
prescribing information. Risk factors for GIP in
patients with RA include a history of
diverticulitis, advanced age, use of
glucocorticoids and/or nonsteroidal
anti-inflammatory drugs (NSAIDs), and
smoking [15–18]. In the TCZ safety analysis,
Curtis et al. reported GIP incidence rates [95%
confidence interval (CI)] of 1.5 (1.1–1.8) per
1000 patient-years (PYs) in the TCZ global
postmarketing safety database population (up
to July 29, 2011) and 2.0 (1.3–2.9) per 1000 PYs
in the TCZ clinical trial population (up to April
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1, 2011); the reported GIP incidence rate
(95% CI) in the aTNF US healthcare claims
database population was 1.4 (1.1–1.8) per 1000
PYs [14]. However, the variety of sources for
event rates limits the ability to compare
between the different therapies, and the
information regarding GIP associated with
TCZ remains limited.
In order to update the currently available
information on GIP events in patients with RA
treated with TCZ, we examined GIP events from
clinical trial and real-world (postmarketing and
healthcare claims) populations. In the current
study, the frequency of adjudicated GIP events
from the TCZ-IV RA clinical trial program
population (data cutoff December 2014) and
the incidence of GIP events from a
postmarketing population in the TCZ global
safety database (cutoff date April 10, 2015) were
studied. Furthermore, data were obtained from a
large administrative healthcare claims database
(data collected from January 1, 2010 to June 30,
2014) to assess the rate of GIP events in patients
with RA treated with TCZ, aTNF agents (overall
and individual agents), and abatacept. The
availability of this healthcare claims data,
which include the baseline characteristics of
the patients, offers the unique opportunity to
compare the incidence rates of GIP between
patients with RA who received TCZ or other
biologics in real-world clinical settings.
The objective of this report was to update the
available GIP safety information associated with
TCZ administration from multiple data sources
(clinical trials database, postmarketing, and
real-world administrative claims) and to
examine whether the frequency in risk of GIP
has changed over time. In addition, the
incidence of GIP from a single real-world
healthcare claims database was compared
between patients with RA who received TCZ,
aTNF agents, or abatacept.
METHODS
Reporting rates of GIP events were estimated in
three distinct patient data sets: a TCZ-IV clinical
trial all-exposure population database (not
including studies performed in Japan), a global
company postmarketing safety database
population, and a publicly available healthcare
insurance claims database population—a
retrospective cohort of patients with RA from
US healthcare claims databases [Truven Health
MarketScan Commercial Claims and
Encounters (commercial) and Medicare
Supplemental and Coordination of Benefits
(Medicare)].
Clinical Trial Database Population
The clinical trial database population included
patients with RA from the 5 core TCZ-IV Phase III
RA clinical trials (OPTION, RADIATE, TOWARD,
AMBITION, and LITHE; ClinicalTrials.gov
identifiers: NCT00106548, NCT00106522,
NCT00106574, NCT00109408, and
NCT00106535, respectively) [5–9], the TCZ-IV
RA lipid study (MEASURE) [19], the TCZ-IV in
early RA study (FUNCTION; ClinicalTrials.gov
identifier: NCT01007435) [13], the TCZ-IV
monotherapy study (ADACTA;
ClinicalTrials.gov identifier: NCT01119859)
[20], and the all-exposure data from the TCZ-IV
long-term extension RA studies. The data cutoff
was December 2014, after the TCZ-IV long-term
extension studies were completed.
Global Postmarketing Safety Database
Population
Reporting rates of GIP events in the global
postmarketing setting were based on AEs
occurring in TCZ-treated patients recorded in
the company postmarketing safety database up
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to April 10, 2015. This database records
information on all spontaneously reported
cases (serious and non-serious) in which TCZ
is per default considered ‘‘suspect’’ and all
non-interventional program/
non-interventional study cases (serious and
non-serious) in which TCZ is considered
‘‘suspect’’; reports from the literature are also
included. All AEs, regardless of whether the
reporter assessed it to be causally related to TCZ,
were included in this analysis.
Classification of GIPs in the Clinical Trial
and Global Postmarketing Safety Database
Populations
Cases were identified by using Standardized
Medical Dictionary for Regulatory Activities
(MedDRA) Queries (SMQs) (‘‘GIP—narrow’’)
version 18.0 for TCZ cases in the global
postmarketing safety and clinical trial
databases. Because the ‘‘GIP—narrow’’ events
included many non-GIP events, these events
were not included in the adjudicated events. All
qualifying cases for ‘‘GIP—narrow’’ went
through an internal medical review
individually in terms of primary reporter type
(medically confirmed or consumer cases),
concomitant medication use, drug–event
latency period, de-challenge and re-challenge
information, event outcome, risk
factors/contributory factors, and concurrent/
underlying medical conditions known to be
associated with GIP. Cases reporting abscess or
peritonitis with no evidence of perforation were
not considered to be GIP events. Based on the
anatomical location of the perforation, all
qualifying GIP events were categorized as
upper GIPs (esophagus, stomach, duodenum,
biliary tract, and gallbladder) or lower GIPs
(jejunum, ileum, cecum, colon, rectum, and
anal region). Reports citing a small intestinal
perforation with no further anatomical details
were categorized as ‘‘lower’’ GIP.
Healthcare Insurance Claims Database
Population
GIP incidence rates were calculated using data
from an external US healthcare claims database
(MarketScan). Adult patients with RA who had
evidence of a prescription for or administration
of a biologic agent between January 1, 2010,
and June 30, 2014, were included: no prior use
of the qualifying biologic, continuous
enrollment for C180 days prior to the index
date, both medical and pharmacy benefit plus
complete data availability during both baseline
and follow-up periods, a minimum follow-up
on the qualifying biologic of 30 days, and—for
the specified population—evidence of prior use
of a biologic other than the qualifying biologic.
The index date was the date of fill of the first
prescription or administration of the qualifying
biologic. Patients with a history of GIP, GI
cancer, ulcerative colitis, or Crohn disease
during the 12 months prior to the index date
were excluded. Patients were followed within
each treatment episode until disenrollment
from MarketScan, end of the study period,
discontinuation of the qualifying biologic,
switch to a new biologic agent, or occurrence
of hospitalization for GIP.
Safety Analysis in the Healthcare
Insurance Claims Database Population
Two definitions of GIP were evaluated in the
healthcare claims databases to generate a best
estimate of the range of the incidence rates of true
GIP [21]. The first definition (sensitive) included
any inpatient admissions with evidence of
perforation based on: (1) the presence of the word
perforation in the following International
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Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM) diagnosis descriptions:
esophageal rupture; gastric, duodenal, peptic, or
gastrojejunal ulcer; appendicitis; and GIP of an
unspecific location in the large intestine; or (2) an
ICD-9-CM diagnosis of diverticulitis,
diverticulosis, or ischemic colitis plus a Current
Procedural Terminology code for suture or
resection of the small or large intestine. The
second definition (specific) included only
inpatient admissions with evidence of
perforation based on the presence of the word
perforation in ICD-9-CM diagnosis descriptions for
esophageal rupture; gastric, duodenal, peptic, or
gastrojejunal ulcers; and unspecified GIP. The
specific GIP definition did not include cases of
appendicitis, diverticulitis, diverticulosis, or
ischemic colitis associated with surgical GI
procedures.
Adjusted incidence rate ratios (IRRs) were
obtained by using Poisson regression and
exponentiating the coefficients. Multivariate
adjustment was performed comparing TCZ
with aTNF combined. The following baseline
covariates were adjusted for in the multivariate
models: age, sex, cumulative oral glucocorticoid
and NSAID use in the 180 days prior to the
index date, history of diverticulitis, number of
prior biologics, and observed duration of RA.
This article is based on previously conducted
studies, and does not involve any new studies of
human or animal subjects performed by any of
the authors.
RESULTS
TCZ-IV Clinical Trial Database Population
The TCZ-IV all-exposure RA clinical trial
population includes data from 5185 patients
who received C1 dose of TCZ-IV and includes all
data from the time of first TCZ dose,
representing 17,905.9 PYs of exposure
(Table 1). From the SMQ ‘‘GIP—narrow’’
search, 70 events were reported in 53 patients.
Of these, 34 events in 31 patients were
adjudicated as GIPs, for an incidence rate (95%
CI) of 1.9 (1.3–2.7) events per 1000 PYs. Of these
34 events, 9 occurred in 9 patients (29%) with a
history of diverticular disease, gastritis, or ulcer,
and 16 occurred in 16 patients (52%) with a
diagnosis of diverticular disease at the time of
surgery or during the course of the clinical trial.
There was no increase in number of GIPs with
increased TCZ exposure or duration of study
(Table 1). The overall incidence rate observed
during greatest PY exposure period
([36 months, with 6872.9 PYs of exposure)
was comparable with rates observed at earlier
time points. The majority of GIPs (85%) in the
TCZ-IV all-exposure population occurred in the
lower GI tract.
In the all-exposure TCZ-IV clinical trial
population, baseline demographic data were
comparable between the overall population
and patients who experienced a GIP (Table 2).
The mean (standard deviation) age was greater
for patients who experienced an adjudicated
GIP than for the overall population:
58.5 (10.6) years compared with 51.7 (12.8)
years—a trend with age being a risk factor for
GIP [17]. The proportion of patients with prior
exposure to aTNF agents was 22.6% for those
who experienced an adjudicated GIP compared
with 17.0% for the overall population. Of
patients with an adjudicated GIP, 17.9% had a
history of smoking compared with 18.0% of
patients in the overall population.
SC-administered TCZ has been studied in 2
RA clinical trials, with a total of 2039 PYs of
exposure (n = 1374). The incidence rate of GIP
events in the TCZ-SC all-exposure population
was slightly lower (1.5 per 1000 PYs) than in the
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TCZ-IV all-exposure population. Given the
limited exposure and lack of increased risk,
data from the TCZ-SC clinical trials are not
included in this analysis.
TCZ Global Postmarketing Safety Database
The SMQ ‘‘GIP—narrow’’ search retrieved 449
events in 437 patients from the global
postmarketing safety database for which a
causal or temporal association between GIPs
and TCZ could not be excluded, for an overall
reporting rate (95% CI) of 1.2 (1.1–1.3) GIP
events per 1000 PYs over 382,621 PYs of
postmarketing TCZ exposure (Table 3).
Of 295 patients with available information
for a comprehensive medical analysis,
perforation occurred in the upper GI tract in
36 patients, the lower GI tract in 202 patients,
and an unspecified location in 60 patients; 3
patients experienced [1 GIP (Table 3). Of the
202 patients with a lower GIP, 152 (75.2%) were
receiving glucocorticoids, 96 (47.5%) were
receiving NSAIDs, 78 (38.6%) were receiving
both glucocorticoids and NSAIDs, and 17 (8.4%)
were receiving aspirin. Also of the 202 patients
with a lower GIP, 135 (66.8%) had reported
diverticular problems, including a medical
history in 23 patients (11.4%; 14 with
diverticulosis, 7 with diverticulitis, and 2 with
both diverticulosis and diverticulitis),
concurrent diverticular disease in 22 patients
(10.9%; 14 with diverticulosis, 4 with
diverticulitis, and 4 with both diverticulosis
and diverticulitis; 1 patient had both
concurrent and medical history of concurrent
diverticular disease), and 91 patients with no
medical history of concurrent condition of
diverticular disease for whom diverticulosis,
diverticulitis and/or diverticular perforation
was reported at the time of GIP diagnosis (7
with diverticulosis, 17 with diverticulitis, 24
with diverticular perforation, 5 with diverticular
perforation accompanied by diverticulosis, 36
with diverticular perforation accompanied by
diverticulitis, and 2 with diverticular
Table 2 Baseline characteristics of TCZ-IV-exposed patients with rheumatoid arthritis in clinical trials
Characteristics Overall (N5 5185) GIP SMQ AEs (N5 53) Adjudicated GIPsa (N5 31)
White, % 75.0 75.5 71.0
RF positive, % 79.0 84.9 87.1
Age, mean (SD), years 51.7 (12.8) 57.2 (13.4) 58.5 (10.6)
Female, % 81.1 75.5 71.0
Weight, mean (SD), kg 73.8 (18.4) 78.4 (16.9) 75.6 (15.2)
Smoker, %b 18.0 26.5 17.9
Prior aTNF use, % yes 17.0 18.9 22.6
Baseline DMARD use, % yes 66.7 64.1 83.9
AE adverse event, aTNF anti-tumor necrosis factor, DMARD disease-modifying antirheumatic drug, GIP gastrointestinal
perforation, IV intravenous, RF rheumatoid factor, SMQ Standard Medical Dictionary for Regulatory Activity Query, TCZ
tocilizumab
a Retrieved cases were adjudicated for evidence of perforation within the GI system: cases reporting abscess or peritonitis
with no evidence of perforation were not considered to be GIP events
b Percentages were based on patients with nonmissing data. In the overall group, 716 of 3986 patients were smokers; in the
adjudicated GIP group, 5 of 28 patients were smokers
Rheumatol Ther (2016) 3:337–352 343
Table 3 GIPs in patients treated with TCZ reported to the global postmarketing safety database
Patients treated with TCZ Number/percentage/95% CIa
Patients with C1 GIP, n 437
Total exposure, PYs 382,621
No. of GIP events 449
No. GIP events per 1000 PYs (95% CI) 1.2 (1.1–1.3)
Upper GIP, nb 36
Concomitant glucocorticoids, n (%) 32 (88.9)
Concomitant NSAIDs, n (%) 20 (55.5)
Both concomitant glucocorticoids and NSAIDs, n (%) 18 (50.0)
Concomitant aspirin, n (%) 3 (8.3)
Medical history of concurrent peptic ulcer disease, n (%) 13 (36.1)
Lower GIP, nb 202
Concomitant glucocorticoids, n (%) 152 (75.2)
Concomitant NSAIDs, n (%) 96 (47.5)
Both concomitant glucocorticoids and NSAIDs, n (%) 78 (38.6)
Concomitant aspirin, n (%) 17 (8.4)
Medical history of concurrent inﬂammatory bowel disease, n (%) 9 (4.5)
Diverticular problems (diverticulitis, diverticulum, diverticulosis), n (%)c 135 (66.8)
No concurrent or medical history of diverticular disease, n (%)d 91 (45.0)
Diverticulosis, n 7
Diverticulitis, n 17
Diverticular perforation, n 24
Diverticulosis and diverticular perforation, n 5
Diverticulitis and diverticular perforation, n 36
Diverticulosis, diverticulitis, and diverticular perforation, n 2
Concurrent diverticular disease, n (%) 22 (10.9)
Concurrent diverticulosis, n 14
Concurrent diverticulitis, n 4
Concurrent diverticulosis and diverticulitis, n 4
Medical history of diverticular disease, n (%) 23 (11.4)
History of diverticulosis, n 14
History of diverticulitis, n 7
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perforation accompanied by both diverticulosis
and diverticulitis).
Of 437 patients with GIP retrieved from the
postmarketing safety database, 21 (4.8%) had
fatal outcomes. In 18 of these 21 patients, GIP
was reported as the underlying event of death.
Of these 18 patients, perforation occurred in the
lower GI tract in 14 patients, the upper GI tract
in 2 patients, and unspecified locations in 2
patients. In the remaining 3 patients, the causes
of death were peritonitis secondary to
perforation of colonic diverticulitis, perforative
peritonitis and disseminated intravascular
coagulation, and unrelated causes.
US Insurance Claims Database
A total of 58,334 patients with RA treated with
an aTNF, abatacept, or TCZ who met the
eligibility criteria for analysis were identified
in the healthcare claims. Patients were
followed for a mean of 535 days. Overall,
approximately 50% of patients had no
evidence of prior exposure to a qualifying
biologic DMARD. However, of the patients
who initiated TCZ, most (88%) had prior
biologic exposure; therefore, the safety
analysis reported in detail here focused only
on the population of patients who had
received C1 prior biologic DMARD.
Of the patients with prior biologic exposure,
the mean age was similar for those who received
an aTNF, abatacept, or TCZ (52.2, 54.4, and
54.1 years, respectively; Table 4). Patients who
received TCZ tended to have received more
prior biologics; 27.3% of patients in the TCZ
group received C3 prior biologics compared
with 11.4% in the abatacept group and 7.8% in
the aTNF group. Similar proportions of patients
across the groups had exposure to prescription
NSAIDs (43.6%, 41.0%, and 41.9% for the aTNF,
abatacept, and TCZ groups, respectively). Mean
exposure to oral glucocorticoids was also similar
across groups.
Of the patients with prior biologic exposure,
there were 21 GIPs (10 from the aTNF group, 5
from the abatacept group, and 6 from the TCZ
group) per the specific definition and 31
(14 from the aTNF group, 8 from the abatacept
group, and 9 from the TCZ group) per the
sensitive definition (Table 5). The GIP incidence
rate (95% CI) per the specific definition for the
TCZ group was 1.8 (0.7–4.0) per 1000 PYs
compared with 0.6 (0.3–1.2) and 0.8 (0.3–2.0)
Table 3 continued
Patients treated with TCZ Number/percentage/95% CIa
History of both diverticulosis and diverticulitis, n 2
History of GIP, n (%) 3 (1.5)
CI conﬁdence interval, GIP gastrointestinal perforation, NSAID nonsteroidal anti-inﬂammatory drug, PY patient-year,
TCZ tocilizumab
a As deﬁned in each row
b Sufﬁcient information for a comprehensive analysis was available for 298 GIP events reported in 295 patients. For 60 of
these patients, the site of GIP was unspeciﬁed. Some patients had more than 1 site of perforation: 2 patients had both a
lower GIP and an unspeciﬁed site of perforation; in 1 patient, only 1 GIP was reported, although in the case details both
upper and lower GIPs were identiﬁed—these have been included as both upper and lower GIPs, respectively
c In one case, both medical history and concomitant condition of diverticular disease were reported
d In these 91 patients, the qualifying event was observed at the time of GIP diagnosis and was either diverticular perforation
or the GIP was associated with diverticular disease (diverticulitis, diverticulum, diverticula)
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per 1000 PYs for the aTNF and abatacept groups,
respectively. According to the specific
definition, the incidence rates (95% CI) for the
individual aTNF agents ranged from 0.4
(0.1–1.4) to 1.3 (0.3–3.8) per 1000 PYs with
widely overlapping CIs. According to the
sensitive definition, the incidence rate (95%
CI) per 1000 PYs for the TCZ group was 2.8
(1.3–5.2) compared with 0.9 (0.5–1.5) and 1.4
(0.6–2.7) for the aTNF (with widely overlapping
CIs) and abatacept groups, respectively. The
majority of GIPs (71.4%) were reported in the
lower GI tract, regardless of treatment or
definition. The lower GI tract perforations
were mostly associated with diverticular
diagnoses, including three cases in the aTNF
group, four in the abatacept group, and two in
the TCZ group.
Table 4 Baseline demographic and clinical characteristics of patients with rheumatoid arthritis and prior biologic exposure
from a healthcare insurance claims database
Characteristics Any aTNF
(N5 17,333)











Female, n (%) 13,762 (79.4) 4505 (78.1) 2932 (79.8) 1835 (78.5) 5190 (82.1) 2999 (83.3)
Age, mean (median), n (%) 52.2 (53) 52.3 (54) 51.7 (53) 52.1 (53) 54.4 (55) 54.1 (55)
65–74 years 1578 (9.1) 525 (9.1) 286 (7.8) 258 (11) 755 (11.9) 398 (11)
C75 years 660 (3.8) 231 (4.0) 126 (3.4) 95 (4.1) 362 (5.7) 183 (5.1)
Prior biologics, n (%)
1 12,687 (73.2) 5033 (87.3) 3098 (84.3) 1520 (65.0) 3392 (53.7) 1462 (40.6)
2 3284 (18.9) 576 (10.0) 444 (12.1) 605 (25.9) 2210 (35.0) 1158 (32.1)
3 943 (5.4) 117 (2.0) 92 (2.5) 155 (6.6) 573 (9.1) 642 (17.8)
4 299 (1.7) 30 (0.5) 31 (0.8) 46 (2.0) 130 (2.1) 244 (6.8)
C5 120 (0.7) 9 (0.2) 10 (0.3) 13 (0.6) 15 (0.2) 96 (2.7)
Duration of prior biologic
exposure, mean (median), days
540 (316) 545.3 (304) 422 (238) 464.9 (282) 643.3 (402) 713.2 (483)
csDMARDs, n (%) 6021 (34.7) 1936 (33.6) 1266 (34.4) 867 (37.1) 2359 (37.3) 1324 (36.8)
NSAIDs, n (%) 7550 (43.6) 2464 (42.7) 1603 (43.6) 1040 (44.5) 2592 (41.0) 1512 (41.9)
Oral glucocorticoids
\7.5 mg/day 8270 (47.7) 2692 (46.7) 1789 (48.7) 1110 (47.5) 3228 (51.1) 1765 (49)
C7.5 mg/day 2156 (12.4) 683 (11.8) 465 (12.7) 367 (15.7) 926 (14.7) 647 (18)
Dose, mean (median), mg/day 5.9 (3.3) 5.5 (3.2) 6.6 (3.3) 7.6 (3.9) 5.9 (3.6) 6.8 (4.2)
CCI, mean (median) 2.3 (2) 2.2 (2) 2.3 (2) 2.3 (2) 2.5 (2) 2.6 (2)
ABA abatacept, ADA adalimumab, aTNF anti-tumor necrosis factor, CCI Charlson Comorbidities Index, csDMARD
conventional synthetic disease-modifying antirheumatic drug, ETA etanercept, IFX inﬂiximab, MOA mechanism of action,
NSAID nonsteroidal anti-inﬂammatory drug, TCZ tocilizumab
a These individual aTNF agents were selected to present because they represent the largest cohorts. The multivariable model
used all ﬁve aTNF agents pooled vs. TCZ
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The unadjusted absolute rate differences (95%
CIs) between the TCZ and aTNF groups for all
GIPs were 1.2 (-0.3 to 2.5) and 1.9 (0.0–3.7) per
1000 PYs per the specific and sensitive definitions,
respectively. For lower GIPs, the unadjusted
absolute rate differences were 1.2 (-0.2 to 2.5)
and 1.8 (0.1–3.6) per 1000 PYs per the specific and
sensitive definitions, respectively.
Table 5 Incidence ratesa of GIPs using sensitive and speciﬁc deﬁnitions in patients with rheumatoid arthritis and prior
biologic exposure from a healthcare insurance claims database
Treatment Speciﬁc deﬁnitionb Sensitive deﬁnitionc
n PYs IR (95% CI) n PYs IR (95% CI)
Any aTNF
All GIP 10 15,925 0.6 (0.3–1.2) 14 15,921 0.9 (0.5–1.5)
Lower GIP 6 15,926 0.4 (0.1–0.8) 10 15,922 0.6 (0.3–1.2)
Etanercept
All GIP 2 3237 0.6 (0.1–2.2) 3 3235 0.9 (0.2–2.7)
Lower GIP 0 3238 0 (0.0–1.1) 1 3235 0.3 (0.0–1.7)
Adalimumab
All GIP 2 5201 0.4 (0.1–1.4) 2 5201 0.4 (0.1–1.4)
Lower GIP 1 5202 0.2 (0.0–1.1) 1 5202 0.2 (0.0–1.1)
Inﬂiximab
All GIP 3 2341 1.3 (0.3–3.8) 3 2341 1.3 (0.3–3.8)
Lower GIP 3 2341 1.3 (0.3–3.8) 3 2341 1.3 (0.3–3.8)
Abatacept
All GIP 5 5940 0.8 (0.3–2.0) 8 5938 1.4 (0.6–2.7)
Lower GIP 5 5940 0.8 (0.3–2.0) 8 5938 1.4 (0.6–2.7)
Tocilizumab
All GIP 6 3268 1.8 (0.7–4.0) 9 3267 2.8 (1.3–5.2)
Lower GIP 5 3268 1.5 (0.5–3.6) 8 3267 2.5 (1.1–4.8)
aTNF anti-tumor necrosis factor, CI conﬁdence interval, GIP gastrointestinal perforation, ICD-9-CM International
Classiﬁcation of Diseases, Ninth Revision, Clinical Modiﬁcation, IR incidence rate, MOA mechanism of action, PY
patient-year
a Incidence rates per 1000 PYs
b The speciﬁc deﬁnition included only inpatient admissions with evidence of perforation based on the presence of the word
perforation in ICD-9-CM diagnosis descriptions for esophageal rupture; gastric, duodenal, peptic, or gastrojejunal ulcers; and
unspeciﬁed GIP. Cases of appendicitis, diverticulitis, diverticulosis, or ischemic colitis associated with surgical GI procedures
were not included
c The sensitive deﬁnition included any inpatient admissions with evidence of perforation based on (1) the presence of the
word perforation in the following ICD-9-CM diagnosis descriptions: esophageal rupture; gastric, duodenal, peptic, or
gastrojejunal ulcers; appendicitis; and GI perforation of an unspeciﬁc location in the large intestine or (2) an ICD-9-CM
diagnosis of diverticulitis, diverticulosis, or ischemic colitis plus a Current Procedural Terminology code for suture or
resection of the small or large intestine
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Multivariate analysis compared adjusted GIP
incidence rates between aTNF and TCZ cohorts
with prior exposure to C1 biologic. The adjusted
IRRs (95%CI) for all GIPs inpatientswho received
TCZ versus those who received an aTNF were 2.2
(0.7–6.6; specific definition) and 2.2 (0.9–5.4;
sensitive definition). For lower GIP events, the
adjusted IRRs in patientswho receivedTCZ versus
those who received an aTNF were 4.0 (1.1–14.1;
specific definition) and 3.1 (1.1–8.4; sensitive
definition). Both the number of prior biologics
and the comorbidities index were significantly
associated with the risk of GIP events [IRR: 1.5
(95% CI, 1.0–2.2), P = 0.036 and 1.2 (95% CI,
1.0–1.4), P = 0.018, respectively].
In the biologic-naı¨ve populations, no
patients treated with TCZ (12% of the overall
TCZ exposure) experienced a GIP; in patients
treated with aTNFs (75-times greater patient
exposure than for TCZ), the GIP incidence rate
was similar to the overall aTNF-exposed
population.
DISCUSSION
The incidence rates of GIP events in patients
treated with TCZ are reported here from three
distinct patient populations: patients from
postmarketing, clinical trial, and real-world
settings. GIP event rates in patients treated
with TCZ ranged from 1.2 to 3.9 per 1000 PYs
for the different populations and per definitions
of a GIP event. In the TCZ-IV all-exposure RA
clinical trials (17,905.9 PYs of TCZ exposure),
the incidence rate of adjudicated GIP events was
1.9 per 1000 PYs; this rate did not increase over
time and was consistent with the incidence rate
in the TCZ-SC all-exposure RA clinical trial
population. In the clinical trial population,
the proportion of patients with a GIP event
was similar between patients with prior DMARD
use and those who were DMARD-naı¨ve;
similarly, no difference was observed between
patients with prior aTNF use and those where
were aTNF-naı¨ve (data not shown). In the global
postmarketing TCZ safety database (382,621 PYs
of TCZ exposure), the reporting rate of GIP
events was 1.2 per 1000 PYs. In the healthcare
claims database TCZ population (3268 PYs of
TCZ exposure), the incidence rate of GIP events
ranged from 1.8 to 2.8 per 1000 PYs; the GIP
incidence rate in the combined aTNF
population (15,921–15,925 PYs of exposure)
ranged from 0.6 to 0.9 per 1000 PYs. In all
three TCZ populations examined here (clinical
trial, postmarketing safety, and healthcare
claims databases), the majority of GIPs
occurred in the lower GI tract.
Our results are consistent with those
reported in a recent analysis by Xie et al. [22]
using data from MarketScan and Medicare
healthcare claims from 2006 to 2014 of
190,061 patients with RA. Using the same
sensitive definition as in our study, they
reported an overall incidence rate of
hospitalized GIP per 1000 PYs of 1.55 for TCZ,
1.29 for tofacitinib, 1.10 for abatacept, 0.73 for
rituximab, and 0.84 for aTNFs (with similar
incidence rates for adalimumab, etanercept, and
infliximab).
Comparison of GIP incidence rates across
biologic therapies for RA is limited by the ability
to make comparisons across different data sets
with different strengths, limitations, and
patient populations. The healthcare claims
database examined in this study provides
real-world data within the same database on
large cohorts of patients with RA who received
biologic therapy. Of patients with prior biologic
exposure, the demographics and baseline
characteristics were mostly similar between
those who received TCZ, aTNF, or abatacept
therapy, except that patients treated with TCZ
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had received more prior biologic therapies
compared with patients treated with aTNF
agents. The rates of GIP were consistently
higher in the TCZ cohort than in the aTNF
cohort per both the specific and sensitive
definitions. The absolute rate difference
between TCZ and aTNFs for all GIPs was 1.2
per 1000 PYs per the specific definition and 1.9
per 1000 PYs per the sensitive definition,
corresponding to numbers needed to harm
(NNH) of 828 and 533, respectively. These
NNHs suggest that, for every 533–828 patients
treated with TCZ for 1 year, 1 additional GIP
event might occur compared with patients
treated with aTNF agents. Of the 471
biologic-naı¨ve patients treated with TCZ, none
experienced GIP, consistent with the
observation that the number of prior biologics
was associated with the risk of GIP. A robust
unbiased comparison of the GIP incidence rates
between TCZ and aTNFs in the biologic-naı¨ve
population is not possible due to the low
exposure of biologic-naı¨ve patients treated
with TCZ compared with aTNFs.
Recently, data from the German biologics
registry RABBIT (RA oBservation of Biologic
Therapy) compared the incidence rate of lower
GIPs in patients with RA treated with TCZ with
those treated with other biologics [23]. The
lower GIP event rate for patients treated with
TCZ was 3.0 events per 1000 PYs compared with
0.5 events per 1000 PYs in patients treated with
aTNF agents (with similar incidence rates
between adalimumab, etanercept and
infliximab). Considering the small number of
patients treated with TCZ who experienced a
lower GIP event (11 patients treated in the
RABBIT registry and 5–8 patients from the
healthcare claims analysis in this study), the
rates of lower GIP events between the RABBIT
analysis and the US healthcare claims database
analysis appear comparable. Importantly,
conclusions regarding the RABBIT analysis are
limited in comparisons of incidence rates
between each cohort without adjustment for
differences in patient and disease characteristics
and medication history.
The strengths of this analysis include the
data source for the healthcare claims database,
which is among the largest proprietary sample
available in the US, making it well suited for the
study of infrequently occurring outcomes such
as GIPs. In addition, the study included patients
from both commercial and Medicare databases,
thus representing both younger and older
patients in the US. The main limitation of this
study was the small number of GIP events for
analysis in both the healthcare claims and
clinical trials database populations. Within the
clinical trials database, the small number of
events was due to both the low event rate and
the limited overall exposure; given this limited
exposure, the event rate was able to be
estimated with relatively high precision. The
addition of three recently completed
randomized controlled trials (MEASURE [19],
FUNCTION [13], and ADACTA [20]) increased
the TCZ-IV all-exposure clinical trial population
from 4009 as reported by Curtis et al. [14] in
2015 to 5185 patients reported here. A
limitation in the healthcare claims database
analysis here was that only information on
prescription medication claims was obtained;
therefore, use of NSAIDs and over-the-counter
medications used to treat GI symptoms was not
captured. Although it likely had an insignificant
effect on the results, it is important to note that
about 5% of patients in the postmarketing
safety database had concurrent or a history of
inflammatory bowel disease, whereas patients
with inflammatory bowel disease in the
healthcare claims database were excluded from
the analysis. Due to variation in reporting
sources and the nature of spontaneously
Rheumatol Ther (2016) 3:337–352 349
reported events, baseline characteristics of the
postmarketing database population could not
be characterized. In addition, events from the
postmarketing population may have been
underreported due to the voluntary nature of
spontaneous safety reporting.
CONCLUSIONS
The rates for the rare GIP event reported here
from TCZ-IV clinical trials and the TCZ
postmarketing database are consistent with
those from previous reports and showed no
increase over time; the vast majority of events
occurred in the lower GI tract and in patients
with underlying undiagnosed diverticulitis. The
GIP event rates from clinical trials and
postmarketing reports were consistent with
rates from a real-world data source of US
healthcare claims, suggesting that GIP events
in real-world clinical practice reflect what has
been observed in the clinical trial program.
Absolute rate differences between the TCZ and
aTNF cohorts from US healthcare claims suggest
that, in patients with prior biologic exposure,
for each additional 1000 patients treated with
TCZ for 1 year, 1–2 additional GIP events might
occur compared with patients treated with
aTNFs. Due to the rareness of GIP and the
limited TCZ exposure in biologic-naı¨ve patients,
joint analyses of large RA biologic registries may
clarify the relative differences between
individual biologics in biologic-naı¨ve patients.
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